CABG = coronary artery bypass graft; D = death; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty; RR = relative reduction; TVR = target vessel revascularization; UTVR = urgent target vessel revascularization

*Primary clinical endpoint
^†The primary endpoint was death, reinfarction, or any TVR at 6 months by intention-to-treat (ITT) analysis (placebo 28.1%[n=242] vs. ReoPro 28.2% [n=241]; p=0.90). Thus, patients were analyzed according to the groups to which they were randomized, regardless of whether they received or adhered to their alocated treatment.
^‡The primary endpoint was a composite of all-cause mortality, reinfarction, ischemia-driven TVR, or disabling stroke during the first 6 months after the index procedure (PTCA 20.0% [n=518], PTCA + ReoPro 16.5% [n=528], stenting 11.5% [n=512], stenting + ReoPro 10.2% [n=524]); P<0.001.^6
§Patients assigned to usual care were administered heparin 10,000 U intra-arterially, followed by intravenous heparin infusion 1000 U/h for the first 12 hours after sheath removal.